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E-mail address: Kathryn.paterson@kcl.ac.uk (K.J. PBradykinin (BK) is an inﬂammatory mediator that can evoke oedema and vasodilatation, and is a potent
algogen signalling via the B1 and B2 G-protein coupled receptors. In naïve skin, BK is effective via consti-
tutively expressed B2 receptors (B2R), while B1 receptors (B1R) are purported to be upregulated by
inﬂammation. The aim of this investigation was to optimise BK delivery to investigate the algesic effects
of BK and how these are modulated by inﬂammation. BK iontophoresis evoked dose- and temperature-
dependent pain and neurogenic erythema, as well as thermal and mechanical hyperalgesia (P < 0.001 vs
saline control). To differentiate the direct effects of BK from indirect effects mediated by histamine
released from mast cells (MCs), skin was pretreated with compound 4880 to degranulate the MCs prior
to BK challenge. The early phase of BK-evoked pain was reduced in degranulated skin (P < 0.001), while
thermal and mechanical sensitisation, wheal, and ﬂare were still evident. In contrast to BK, the B1R selec-
tive agonist des-Arg9-BK failed to induce pain or sensitise naïve skin. However, following skin inﬂamma-
tion induced by ultraviolet B irradiation, this compound produced a robust pain response. We have
optimised a versatile experimental model by which BK and its analogues can be administered to human
skin. We have found that there is an early phase of BK-induced pain which partly depends on the release
of inﬂammatory mediators by MCs; however, subsequent hyperalgesia is not dependent on MC degran-
ulation. In naïve skin, B2R signaling predominates, however, cutaneous inﬂammation results in enhanced
B1R responses.
 2013 International Association for the Study of Pain. Published by Elsevier B.V.
Open access under CC BY license. 1. Introduction
Kinin peptides, in particular, bradykinin (BK), are endogenously
released from high-molecular-weight plasma globulin kininogen
precursors at the site of tissue injury and/or inﬂammation by kal-
likrein-mediated hydrolysis [13]. BK was originally identiﬁed to
cause vascular smooth muscle relaxation and nonvascular smooth
muscle contraction (Rocha e Silva in 1962, as referenced [28]). Fur-
ther investigation in man revealed BK as an algogenic peptide from
inﬂammatory exudates, for example, ﬂuid from arthritic joints and
cantharadin blisters [2].
BK acts via 2 G-protein coupled receptors: B1 and B2 receptors
with36% sequencehomology [45]. Receptor activation triggersmul-
tiple intracellular signalling pathways [13,56]. B2 receptors (B2R)
are constitutively expressed on primary sensory nerve terminalstudy of Pain. Published by Elsevie
don, Wolfson Centre for Age-
y’s Campus, London SE1 1UL,
.
aterson).[50,51]. Meanwhile the presence and functionality of purportedly
injury-inducible B1 receptors (B1R) remains controversial.
Acting via the constitutively expressed B2Rs in different tissues,
BK has been shown to activate intracellular signalling pathways
that result in vasodilatation, neutrophil chemotaxis, and increased
vascular permeability [38]. Several studies have investigated the
vasodilatory actions of BK in man, mostly in the forearm
[9,29,48]. BK has been shown to evoke dose-dependent pain
[26,43] and itch [38] when administered via injection, or by ionto-
phoresis [9,30]. Some of the pain-producing effects of BK probably
arise from a direct action on nociceptors (as seen in relatively pure
dorsal root ganglion cell cultures), or from an indirect action via
other cells expressing BK receptors.
In human skin, mast cells (MCs) are found in the superﬁcial der-
mal zone adjacent to the dermal-epidermal junction containing
granules rich in components such as histamine and heparin. Spa-
tially clustered surrounding capillaries with increased density dis-
tally in a glove-and-stocking distribution, there are reputedly
approximately 100 MC/mm2 in forearm skin [32]. In our experi-
ment we applied BK to an 18-mm-diameter circular area likely tor B.V. Open access under CC BY license. 
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MC activation [32]. However, species and tissue may explain dis-
crepancies in the literature, for example, MC activation by BK in
murine spleen [32] and rat peritoneum [40], but not in human his-
taminocytes [40] or epidermal cultures [6,51]. B2Rs have been re-
ported on human oesophageal MCs [18], but other tissues remain.
Given these uncertainties, we wished to evaluate the in vivo con-
tribution of MCs to BK effects in human skin.
B1R expression is reported to be induced on IB4+ nonpeptider-
gic sensory neurons following tissue injury [13,19,51]. A role for
B1R in postinjury sensitisation has been demonstrated in rodents
using selective antagonists for reversal of thermal and mechanical
hyperalgesia in adjuvant and ultraviolet B (UVB)-induced inﬂam-
mation [50]. However, while B1R agonists have failed to directly
stimulate sensory neurons in inﬂammatory states [15,46,55], non-
neuronal B1R upregulation suggests an indirect role in nociceptor
stimulation [15].The role of the B1R therefore demands further
investigation, which we have undertaken here using UVB as an
inﬂammatory stimulus.
In the current experiments, we sought to optimise a method for
delivering BK to human skin as well as study mechanisms of BK-
evoked pain.
2. Methods
Healthy volunteerswere recruited to take part in this study. Each
participantprovidedwritten informedconsentprior to commencing
each experiment, and the protocol was conducted in accordance
with the King’s College London ethics committee (BDM 10/11-84).
Individuals with known skin hypersensitivity or dermatological
conditions such as eczema or dermatitis were excluded from all
experiments. The UVB experiment solely included individuals with
skin type 2 or 3 according to the Fitzpatrick scale [3], as established
during initial screening. All participants were asked to refrain from
analgesic, antiinﬂammatory, or antihistamine medications for
4 hours, and caffeine or nicotine for 1 hour prior to the experiment.
2.1. Iontophoresis
Subjects were comfortably seated in a chair with their arm at
the level of the right atrium. Left and right distal volar forearms
were alternately tested at sites >4 cm apart. Each experimental site
was prepared using an alcohol swab (70% isopropyl alcohol, Uni-
Wipe; Universal Hospital Supplies, London, UK). The iontophoresis
unit (Phoresor II PM700, Iomed Inc, Salt Lake City, UT, USA) com-
prised a constant current stimulator and a wire electrode, which
runs around the inner circumference of a custom-made perspex
ring of 18 mm internal diameter. This perspex chamber was afﬁxed
to the skin using a circular adhesive patch around the external rim
and ﬁlled with 1 mL solution as designated per condition. BK and
des-Arg9-BK (both from Sigma, Poole, UK) solutions were freshly
prepared as 1 mg/mL solution in 0.9% physiological saline per
experiment, and comparison was made to 0.9% saline alone. Inher-
ent to the iontophoresis method, the exact dose of compound can-
not be quantiﬁed, but is proportional to the charge delivered. That
is, iontophoretic delivery of a charged molecule is dependent upon
current strength and time of application, following Coulomb’s law;
as the product of current and time [52]:
q ¼ I t;
where q = charge (mC), I = current (mA), and t = time (seconds).
BK, in solution, dissociates into positively charged ions. There-
fore, to drive these ions across the skin, the positive lead of the cur-
rent source was connected to the wire chamber electrode and the
negative lead attached to a conductive pad on the outer palm of the
ipsilateral hand, which serves as a reference.2.2. Visual analogue scale
Participants were automatically prompted to rate the sensation
along a digital visual analogue scale (VAS) at the iontophoretic site
every 20 seconds throughout the 8-minute iontophoresis. The VAS
was represented by a horizontal bar on a computer screen (0 = no
pain, 100 = maximal intensity pain imaginable). The participant
clicks themouse at the point along the line that most accurately de-
scribes the sensation at that instant when instructed by the soft-
ware (Sensation Logger, bespoke, UK). Following each rating, the
cursor automatically reverts to 0, and there are no gradations along
the line to ensure that the participant rates the sensation as an arbi-
trary quantiﬁcation of their maximal perceived pain every time.
2.3. Measurement of ﬂare area
The area of solid ﬂare was measured planimetrically through
tracing onto acetate. The area was calculated using an 8-spoke
wheel (each spoke oriented at 45 intervals) to calculate the total
area in square cm, from which the primary area of iontophoresis
(18-mm internal diameter circular chamber) was subtracted [49].
2.4. Assessment of pain thresholds
Mechanical and thermal pain thresholds were ascertained fol-
lowing selected relevant protocol from the validated and robust
battery of standardised Quantitative Sensory Testing as developed
by the German Research Network on Neuropathic Pain (DFNS) [53].
These short-form tests were performed by a DFNS-trained experi-
menter, the same experimenter throughout to avoid interexperi-
menter variability. Following initial demonstration and
instruction for both tests, subjects kept eyes closed throughout
testing.
Mechanical pain thresholds were measured at the testing site
according to DFNS protocol using a set of 7 custom-made weighted
pinprick stimuli (Pinprick, MRC Systems GmbH, Heidelberg, Ger-
many). Each had an identical 2-mm ﬂat contact surface area with
rounded edges to avoid physical probe contact that would facilitate
nociceptor activation. Each probe exerted ﬁxed force (8, 16, 32, 64,
128, 256, or 512 mN) [4,42]. The pinpricks were applied individu-
ally at a rate of 2 seconds on, 2 seconds off in ascending order until
the stimulus was perceived as ‘‘sharp,’’ then applied in descending
order until perceived as ‘‘blunt.’’ The threshold was deﬁned by the
‘‘method of limits’’ as the geometric mean of 5 measurements of
sharp and blunt in a sequential series of ascending and descending
stimuli.
Heat pain threshold was derived as the arithmetic mean of 3
consecutive measurements using a thermal sensory analyser
(TSA 2001-II; Medoc Ltd, Ramat Yishai, Israel) thermode held
against the skin [1,25]. Thresholds were obtained using ramped
stimuli (1 C/s), which terminated when the subject pressed a but-
ton to indicate ﬁrst percept of pain. Temperature of the thermode
declined to baseline temperature of 32 C (centre of neutral range)
at a rate of 5 C/s and remained at 32 C during 10-second inter-
stimulus intervals. The contact area of the thermode was 256 mm2
(16  16 mm). A maximal cut-off temperature of 52 C was em-
ployed whereby the thermal sensory analyser would automatically
return to baseline temperature. All subjects were unaware of the
timing of initiation of temperature increase and the interstimulus
intervals. Thermal testing was ﬁrst demonstrated over an area that
was not used for testing during the experiment, that is, the dorsum
of the hand. The skin was initially inspected for lesions or scarring,
which may alter sensory perception.
During all experiments, participants were blinded to the current
and nature of the solution being administered (ie, whether vehicle
control or test solution). The experimenter was also blinded as to
Fig. 1. Basic process common to all experiments described.
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pseudorandomised sequence. Following each iontophoresis ses-
sion of a test solution, the chamber was removed, ﬂare measured,
and sensory tests conducted as per Fig. 1.
2.5. Assessment of the effects of iontophoretic current on BK-evoked
pain
Forearm skin was maintained at 35 C using an infrared radiant
lamp and monitored throughout the experiment using a noncon-
tact convergent infrared laser thermometer (DT-8861; ATP Instru-
mentation Ltd, Ashby-de-la-Zouch, UK) whilst temporarily
averting the lamp. Iontophoresis of test solutions using currents
of 0.4, 0.8, and 1.2 mA over 8 minutes was performed. BK or saline
were iontophoresed at all doses to independent sites in random se-
quence. Following iontophoresis, the chamber was removed, the
ﬂare measured, and sensory tests conducted as per Fig. 1.
2.6. Assessment of the effects of skin temperature on BK-evoked pain
Forearm skin temperature (25, 30, 35, 40 C) was modulated
using either a gel-ﬁlled cooling refrigerant pack at an appropriate
temperature or an infrared lamp, as appropriate. Temperature
was monitored throughout the 8-minute iontophoretic protocol
using a convergent infrared laser beam thermometer (DT-8861,
ATP Instrumentation Ltd) whilst temporarily removing either the
heating or cooling source. At target temperature, iontophoresis
was initiated at 1.2 mA over 8 minutes. In randomised order, BK
(1 mg/mL in saline) and saline were iontophoresed at all test tem-
peratures to independent volar forearm sites.
2.7. Mast cell degranulation
Compound 4880 (5 mM in deionised water; Milli-Q; Millipore,
Livingston, UK), known to degranulate MCs, was iontophoresed
at 0.4 mA  8 minutes using an 18-mm-diameter perspex chamber
to the volar forearm bilaterally at the same position equidistant be-
tween antecubital fossa and wrist. Iontophoresis was performed 5
times in total, at time 0, and then at 3 hours, 6 hours, 9 hours, and
24 hours to ensure MC depletion [20]. As a measure of depletion,
area of ﬂare was measured immediately following each session
once the chamber and solution had been cleared from the site
and the exact location of the chamber marked onto the skin.
One hour following the ﬁnal ﬂare measurement (at 24 hours
from the beginning of the experiment), the area was left for 3 hours
prior to iontophoretic application to the same site of either BK
(1 mg/mL in 0.9% saline) or saline using 1.2 mA  8 minutes, main-
tained at 35 C using infrared heat lamp as described above.
2.8. Comparison of BK and des-Arg9-BK in naïve skin
B2R selective agonist BK, B1R selective agonist des-Arg9-BK
(both 1 mg/mL in saline) and saline solutions were iontophoresed
in random sequence to independent forearm sites sequentially
alternating arms. All iontophoresis sessions were conducted
maintaining skin temperature at 35 C using a current of
1.2 mA  8 minutes.2.9. Comparison of BK and des-Arg9-BK in UVB-irradiated skin
UVB irradiation was administered using Philips (Guilford, Sur-
rey, UK) TL01 ﬂuorescent bulbs with a maximum wavelength of
311 nm. The irradiance output was measured with a photometer
(IL1400A with SEL240/UVB-1/TD ﬁlter; ABLE Instruments and Con-
trols, Aberdeen, UK) placed at the distance of the exposed skin. This
reading was used to calculate the time needed to deliver an appro-
priate UVB dose. In this manner, a skin-type-speciﬁc UVB dose irra-
diation series was given by exposing volar forearm skin to 6 areas
of 16  16 mm areas of increasing UVB exposure given by the
equation: Energy = Lamp Irradiation  Time [60], as described
elsewhere [7]. At 48 hours post irradiation, each square was as-
sessed for mean erythematic dose (MED). This same dose of UVB
irradiation was then administered to 3 naïve volar forearm sites
bilaterally. At 48 hours post irradiation, the B1R selectivity exper-
iment was repeated at the 3 irradiated sites.
2.10. Data evaluation
All statistical analyses were performed using GraphPad Prism
(La Jolla, CA, USA).
All pain rating data were presented both as mean rating per 20-
second timepoint and mean of individual area under the curve
(AUC) data for each condition. All data were analysed for their dis-
tribution properties using the Shapiro-Wilk test for normality.
Mechanical pain threshold data were found to be normally dis-
tributed in log-space and therefore transformed logarithmically
before statistical analysis [53]. Differences between normally dis-
tributed vehicle and test compound data for each condition were
compared using a repeated-measure 2-way analysis of variance
(ANOVA) with Bonferroni post hoc analysis. Log-data of thresholds
were re-transformed to linear values representing the original unit
of the test and presented as such. All data are presented as
mean ± SEM unless otherwise stated.
3. Results
3.1. Iontophoretic delivery of BK to skin evokes ongoing pain as well as
thermal and mechanical hyperalgesia
As BK is a positively charged molecule, we wanted to establish a
protocol for the iontophoretic delivery, which would enable con-
trolled application of the molecule to the skin, in order to study
evoked pain and the sensitising effects of BK. Increasing doses of
iontophoretic current (from 0.4 to 1.2 mA) were used to enhance
BK delivery. BK iontophoresis rapidly produced pain within the
ﬁrst minute of iontophoresis. Interestingly, there were 2 peaks of
BK-evoked pain, at approximately 2 minutes and 5 minutes from
the start of iontophoresis, and following the second peak there
was a decline in the BK response.
There was a clear current dose-dependent effect on pain as
rated on the VAS scale during the 8-minute period of iontophoresis
(Fig. 2A). Using AUC analysis, the effect of BK was signiﬁcantly dif-
ferent from saline using a current of 1.2 mA (Fig. 2B; P < 0.001,
n = 10, 2-way ANOVA with Bonferroni post hoc analysis). This
dose-dependent effect was conﬁrmed by the demonstration of
Fig. 2. Investigating dose-dependent pain following bradykinin (BK) administration. (A) Pain ratings during iontophoresis of BK and saline vehicle. Displayed as average at
each 20-second timepoint. (B) Area under the curve (AUC). Pain ratings during 8-minute iontophoresis compound administration. Results displayed as average n = 10 with
SEM. ⁄⁄⁄P < 0.001, 2-way repeated-measures analysis of variance with Bonferroni post hoc analysis; n = 10. (C) Saline visual analogue scale (VAS) AUC data plotted at each
dose to demonstrate any linearity with dose response; R2 = 0.0334. (D) BK VAS AUC data plotted at each dose to demonstrate any linearity with dose response; R2 = 0.9683.
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saline (Fig. 2C).
Thermal pain thresholds were reduced after BK treatment
(Fig. 3A). The effect was dose dependent and was seen following
doses of 0.8 mA and 1.2 mA. Interestingly, the highest dose of sal-
ine produced a signiﬁcant increase in heat pain threshold.
Following BK administration, a trend of reduced mechanical
pain threshold was demonstrated in comparison to saline control
under the same conditions (Fig. 3B). This mechanical hypersensi-
tivity was greatest with 1.2-mA currents (P = 0.01, n = 10, paired
t-test). The area of ﬂare generated by application of BK was dose-
dependently greater than that produced by vehicle control under
all conditions (Fig. 3C) (P < 0.001, n = 10, 2-way ANOVA with Bon-
ferroni post hoc analysis). This effect is highly correlated at the
higher doses, as demonstrated by Fig. 3D (0.4 mA R2 = 0.0061;
0.8 mA R2 = 0.1821; 1.2 mA R2 = 0.3394).
3.2. Skin temperature inﬂuences thermal and mechanical sensitisation
following BK delivery
To determine impact of skin temperature on the effects seen by
the exogenous application of BK, the site was maintained at a con-
stant temperature (25, 30, 35, 40 C) throughout the 8-minute
iontophoretic delivery. During the administration of both solu-
tions, dose remained constant at 1.2 mA. Pain ratings during ionto-
phoresis were virtually indistinguishable between BK and saline
control, whilst skin temperature was maintained at 25, 30, and
40 C (Fig. 4A and B). Only while skin temperature was held at
35 C was a biphasic response demonstrated during BK delivery
(Fig. 4A). Using AUC (Fig. 4B), the pain ratings during BK adminis-
tration were shown to be signiﬁcantly increased at 35 C compared
to saline vehicle control (P < 0.001, n = 10, 2-way ANOVA with Bon-
ferroni post hoc analysis), which is diminished at this temperature.The sensitising and ﬂare-inducing effects of BK, however, were
not so temperature dependent. We observed a clear and statisti-
cally signiﬁcant thermal sensitisation at all skin temperatures ex-
cept at 40 C (Fig. 4C). Mechanical sensitisation was signiﬁcant at
35 C and 40 C and approaches signiﬁcance at 30 C (Fig. 4D).
While BK consistently produced greater ﬂare than saline under
each condition, this was again maximal at the physiological tem-
perature of 35 C (Fig. 4E; P < 0.001, n = 10, 2-way ANOVA with
Bonferroni post hoc analysis).
Together, these results show that BK iontophoresis results in
thermal and mechanical hyperalgesia and a clear ﬂare response,
and at higher doses, pain. Effects were optimal at a skin tempera-
ture of 35 C, close to that typically found under normal physiolog-
ical circumstances, and using an iontophoretic current of 1.2 mA.
These optimised conditions were therefore used to further investi-
gate the action of BK in vivo.
3.3. Effects of MC degranulation on evoked pain, ﬂare, and sensitivity
Gradual MC degranulation over time was conﬁrmed by mea-
surement of ﬂare following each application of compound 4880
(Fig. 5A). Wheal responses were initially uniform and large, but
with subsequent applications of compound 4880 they were frag-
mented and greatly reduced. Pain ratings were recorded during
both BK and saline iontophoresis under optimised conditions
(1.2 mA  8 minutes at 35 C) in both naïve and MC degranulated
skin. For clarity, the difference between BK and saline pain ratings
on a VAS scale (BK minus saline at each 20-second timepoint) are
compared in both naïve and degranulated skin (Fig. 5B). In naïve
skin, a characteristic biphasic response was seen, with peaks at
approximately 120 and 300 seconds. However, in degranulated
skin, considerably less pain was reported throughout the trial,
and the later peak seen in control was absent. The difference (BK
Fig. 3. Quantitative testing following 8-minute application. (A) Heat pain thresholds (HPT). (B) Mechanical pain thresholds (MPT) were logarithmically transformed and
paired t-tests performed. 0.8 bradykinin (BK) vs saline P = 0.044, 1.2 mA P = 0.01. (C) Area of ﬂare following each treatment. n = 10 with SEM. (A, C) Two-way repeated-
measures analysis of variance with Bonferroni post hoc analysis. VAS, visual analogue scale; AUC, area under the curve.
786 K.J. Paterson et al. / PAIN

154 (2013) 782–792 saline) in naïve and degranulated skin was found to be signiﬁ-
cant by AUC analysis (Fig. 5C, P = 0.02, n = 10, paired t-test).
The thermal hyperalgesia elicited by BK, however, was indistin-
guishable in naïve and degranulated skin (Fig. 5D, P = 0.039 in MC
degranulated skin [BK vs control], P < 0.001 in naïve, one-way
ANOVA).
Similarly, mechanical hyperalgesia was seen following BK ion-
tophoresis to a similar degree in both naïve and degranulated skin
(Fig. 5E). Therefore, the sensitising effects of BK, unlike the pain-
producing effects, are unaffected by depletion of MC products.
BK-evoked ﬂare exceeded that caused by saline in both naïve
and degranulated skin (Fig. 5F). However, in the absence of MC
products, ﬂares were signiﬁcantly smaller (P < 0.001 in naïve,
P = 0.035 in degranulated skin, n = 10, one-way ANOVA with Bon-
ferroni post hoc analysis).
3.4. The effects of the B1 receptor agonist des-Arg9-BK in naïve skin
BK, known to have great afﬁnity for B2R, was compared under
optimised conditions to the B1R agonist des-Arg9-BK in naïve skin.
The characteristic twin peak time proﬁle of pain rated during
iontophoresis of BK was not seen during application of the B1
receptor agonist des-Arg9-BK (Fig. 6A). Quantiﬁed by AUC
(Fig. 6B), BK evoked signiﬁcantly greater pain ratings over time
than both saline (P < 0.001) and des-Arg9-BK (P = 0.02; n = 10,
one-way ANOVA with Bonferroni post hoc analysis). In naive skin,
des-Arg9-BK evoked painful sensation not statistically different
from saline.
Des-Arg9-BK iontophoresis did not induce the thermal sensiti-
sation seen with BK (Fig. 6C).
Mechanical hyperalgesia was observed by both BK and des-
Arg9-BK iontophoresis using pinprick stimuli (Fig. 6D).
Area of ﬂare evoked by des-Arg9-BK was highly variable
amongst the group of 10 subjects tested. The result was that the
ﬂare elicited by the B1 agonist in naïve skin was statisticallyunchanged from ﬂare evoked by saline, while BK, as expected,
evoked a clear and signiﬁcant ﬂare (Fig. 6E).
3.5. The effects of the B1 agonist des-Arg9-BK in skin inﬂamed with
UVB
We compared the effects of B1 and B2 ligands (des-Arg9-BK and
BK, respectively) in UVB-irradiated skin using methods previously
described [7,16], based upon previous reports that the B1 receptor
is induced under such conditions. We compared iontophoretic
application of des-Arg9-BK with BK in a group of subjects who
had received a modest dose (1 Minimal Erythema Dose (MED)) of
UVB irradiation. These were the same subjects who were tested
with des-Arg9-BK in normal skin.
Pain ratings during iontophoresis were, on average, higher with
des-Arg9-BK compared with BK in inﬂamed skin, and, of course, in
contrast to the effects seen in naive skin (Fig. 7). Total VAS scores
were similar in naïve and inﬂamed skin, but the response in in-
ﬂamed skin appeared monophasic rather than biphasic. Des-
Arg9-BK evoked about the same peak level of pain, but this was
more sustained throughout the application period.
Also, in contrast to normal skin, BK and des-Arg9-BK produced
similar reductions in heat pain thresholds in inﬂamed skin. This
was not seen with saline iontophoresis (Fig. 8A; P = 0.024, n = 10,
one-way ANOVA with Bonferroni post hoc analysis). The magni-
tude of kinin-induced hyperalgesia is lower than that seen in naïve
skin, which may be explained by the heat pain thresholds already
being reduced in UVB inﬂamed skin.
Des-Arg9-BK evoked a modest but statistically signiﬁcant
mechanical hyperalgesia in inﬂamed skin (Fig. 8B; P = 0.003,
n = 10, one-way ANOVA with Bonferroni post hoc analysis), again
in contrast to its effects in normal skin. BK in inﬂamed skin elicited
only a small average mechanical hyperalgesia and this was not sig-
niﬁcant (Fig. 8B), perhaps again because mechanical pain thresh-
olds are already lower in inﬂamed skin and there is therefore a
Fig. 4. Iontophoresis maintaining constant temperature. (A) Pain ratings during bradykinin application. (B) Pain ratings during saline application. (C) Area under the curve
(AUC) of average visual analogue scale (VAS) at each 20-second timepoint for each condition. Results displayed as average n = 10 with SEM. One-way analysis of variance
(ANOVA) with Bonferroni post hoc analysis, ⁄⁄⁄P < 0.001. (D) Heat pain thresholds. (E) Mechanical pain threshold. (F) Flare area. (A, C) Two-way ANOVA with Bonferroni post
hoc analysis. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001. (E) Paired t-tests performed on log-transformed data. HPT, heat pain threshold; MPT, mechanical pain threshold.
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Arg9-BK both produced signiﬁcant ﬂare responses in inﬂamed skin
(Fig. 8C; P < 0.001, n = 10, one-way ANOVA with Bonferroni post
hoc analysis). BK-induced ﬂares were comparable to those seen
in normal skin (in terms of area). Flare evoked by des-Arg9-BK
was less than that produced by BK, but was signiﬁcantly greater
than that seen with saline (P = 0.026, n = 10, one-way ANOVA with
Bonferroni post hoc analysis).
In summary, these results reveal a clear emergence of B1-med-
iated algesic effects in inﬂamed skin that is not observed in normal
skin.
4. Discussion
We have developed an experimental human pain model
employing BK iontophoresis in order to dissect the mechanisms
by which this molecule evokes pain and sensitisation. BK evoked
pain in a dose- and temperature-related manner during iontopho-
resis. This was associated with the development of a cutaneous
ﬂare and thermal hyperalgesia as seen previously [43], in addition
to mechanical hyperalgesia also seen here. The ﬂare and BK-evoked
pain were partly dependent on MCs. The induced mechanical and
thermal hyperalgesia, however, were MC independent. In naiveskin, des-Arg9-BK, which shows selectivity for the B1R (vs BK,
which has selectivity for the B2R) evoked minimal pain and had
only mild sensitising effects. The effects of des-Arg9-BK were, how-
ever, potentiated following UVB irradiation of the skin. This is,
therefore, a robust model system in which to probe the sensitising
effects of BK, and emphasises the enhanced role of B1Rs in inﬂam-
matory pain states.
Being a charged molecule, BK lends itself to administration by
the noninvasive method of iontophoresis. The precise dose deliv-
ered during iontophoresis, while unknown, is proportional to the
magnitude and duration of applied current. We chose this method
of application because achieving a steady state level of BK in the
skin by continual application is arguably more representative of
the physiological inﬂammatory condition than bolus injection,
which likely diffuses rapidly from the area.
We have used a range of doses and temperature conditions to
demonstrate a dose-dependent induction of pain and sensitisation
by BK; these effects were maximal at the highest current used
(1.2 mA) and at 35 C. However, one important ﬁnding is that the
pain-producing effects of BK require higher doses than the sensitis-
ing effects; in particular, the thermal hyperalgesic effect. A dose-
dependent algogenic effect of BK is supported by previous studies
following injection or microdialysis in human skin [22,36,43]. The
Fig. 5. Mast cell degranulation. (A) Mast cell degranulation by repeated iontophoretic application of compound 4880. Extent of mast cell degranulation indicated by size of
ﬂare outside of primary site. (B) Difference between pain ratings during iontophoresis of bradykinin (BK) and saline in both naïve and mast cell degranulated skin. (C) Area
under the curve (AUC) for the difference between pain ratings as shown in (B); paired t-test; P = 0.02. Quantitative sensory testing following iontophoretic application of
saline or BK in both naïve and mast cell degranulated skin. (D) Heat pain thresholds (HPT) naïve P < 0.001, degranulated P = 0.039. (E) Mechanical pain thresholds (MPT) naïve
P < 0.001, degranulated P = 0.002. (F) Area of ﬂare naïve P < 0.001, degranulated P = 0.035. A and C both use one-way analysis of variance with Bonferroni post hoc analysis.
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complex. BK robustly evoked pain at 35 C, but not at lower tem-
peratures. In light of evidence that prolonged (30 minutes) expo-
sure to the full range of temperatures used here were not
inherently painful [10], we can be conﬁdent that any effect seen
is attributable to BK. Evidence suggests that nociceptor excitation
by BK is mediated via transient receptor potential V1 (TRPV1)
and TRPA1 ion channels [5]. BK has a striking ability to induce ther-
mal sensitisation of nociceptive afferents [41]. BK has also been
demonstrated to lower the thermal activation threshold of TRPV1
to below 37 C [58]; these interactions may explain the tempera-
ture dependence of BK-evoked pain. Interestingly, at a skin tem-
perature of 40 C, BK at the same dose did not evoke pain. This
may feasibly be due to temperature-enhanced vasodilatation
increasing compound clearance or enhanced enzymatic cleavage.
The temperature dependence of the sensitising effects of BK were
quite distinct: whilst thermal and mechanical hyperalgesia are
both clearly observed at 35 C, thermal hyperalgesia is also seen
at the lower temperatures tested (25 and 30 C), but not at the
higher temperature of 40 C. Meanwhile, mechanical hyperalgesia
shows the opposite pattern (sensitisation observed at tempera-
tures above but not below 35 C). The molecular explanation forthese differences is not clear, but it is known that the mechanical
and thermal transducers are different and subject to independent
controls.
The time course of pain evoked by continuous iontophoresis of
BK was interesting. We observed 2 peaks in pain ratings, at approx-
imately 120 seconds and 300 seconds following onset of iontopho-
resis. Each peak was followed by a decline in ratings, which may be
explained by tachyphylaxis, a phenomenon consistently reported
by previous studies. Declining pain reports are unlikely to be ex-
plained by psychological acclimatisation, BK metabolism, or dilu-
tion of the peptide in accumulating ﬂuid. Desensitisation of the
B2R receptor, however, is another possibility, as demonstrated
in vitro [24]. The second peak in evoked pain is likely to represent
the engagement of a different mechanism, as discussed below.
There is debate as to what extent BK evokes mechanical
hyperalgesia. Following intradermal injection, no evidence of
mechanical hypersensitivity was found in human volunteers [43],
although mechanical hypersensitivity has been reported following
intradermal injection in rat [35]. We found a clear mechanical
hyperalgesia following iontophoresis of BK. This robust effect com-
pared to the conﬂicting results following injection may be as a con-
sequence of the more prolonged BK application that is possible
Fig. 6. Application of a B1R agonist in naïve skin. (A) Pain ratings during 8-minute iontophoresis of saline, bradykinin (BK), and des-Arg9-BK using a visual analogue scale
(VAS; 0-100). (B) Area under the curve (AUC) from Fig 8A. Saline vs BK P < 0.001, BK vs des-Arg9-BK P = 0.02, n = 10, one-way repeated-measures analysis of variance (ANOVA)
and Bonferroni post hoc analysis. Comparing BK, Des-Arg BK, and saline vehicle control in naïve skin. (C) Heat pain threshold (HPT). Saline vs BK P < 0.001, BK vs Des-Arg9-BK
P = 0.018. (D) Mechanical pain threshold (MPT) saline vs BK P < 0.001, saline vs Des-Arg9-BK P = 0.04. Data log transformed and paired t-tests performed. (E) Flare area saline
vs BK P < 0.001. (C) and (D) both use one-way ANOVA with Bonferroni post hoc analysis.
Fig. 7. Investigating B1R selective agonist in ultraviolet-irradiated skin. (A) Pain ratings during iontophoresis, using visual analogue scale (VAS) at 20-second intervals. (B)
Area under the curve (AUC) of pain ratings. Saline vs bradykinin (BK) (P = 0.04), Saline vs des-Arg9-BK (P = 0.004), BK vs des-Arg9-BK (P = 0.014), one-way analysis of
variance + Bonferroni post hoc analysis n = 10.
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sequence of peripheral or central sensitization. Certain primary
afferent populations (such as feline articular afferents) have beenshown to be sensitised to mechanical stimuli in response to BK
[47]; sensitisation of cutaneous nociceptors to mechanical stimuli
following BK has not, however, been observed either in rat
Fig. 8. Comparing saline, BK, and des-Arg9-BK in inﬂamed skin. (A) Heat pain threshold (HPT). Saline vs des-Arg9-BK P = 0.024, saline vs BK P = 0.024. (B) Mechanical pain
threshold (MPT). Saline vs Des-arg P = 0.003. (C) Area of ﬂare. Saline vs BK P < 0.001, BK vs des-Arg9-BK P = 0.026. (A) and (C) analysed using one-way repeated-measures
analysis of variance + Bonferroni post hoc analysis. (B) Analysed by paired t-tests on log-transformed data.
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human Mechano-heat sensitive C (CMH) ﬁbres [54]. The mechani-
cal hyperalgesia evoked by BK may, rather than a direct nociceptor
effect, be mediated by the BK-evoked release of other mediators
such as Adenosine Tri-Phosphate (ATP) [17] or prostanoids [19,40].
Following iontophoresis of BK, we observed thermal hyperalge-
sia, as others have previously reported following injection of this
agent [43]. There is strong evidence for a peripheral component
of such hyperalgesia. That is, BK has been shown to sensitise ro-
dent [37], nonhuman primate [36], and human [54] nociceptors
to thermal stimuli. BK has been shown to enhance heat-induced
currents in cultured sensory neurons, an effect dependent on acti-
vation on PKC epsilon [11]. The lowering of the threshold of TRPV1
to thermal stimuli by BK has been discussed above and may be
partly mediated by the release of lipoxygenase products of arachi-
donic acid in response to BK [57].
Some of the effects of BK on nociceptive afferents may be indi-
rect and mediated via other cells, such as MCs [21,31]. MCs are a
well-recognised source of mediators such as histamine, the release
of which can be triggered under a variety of circumstances, includ-
ing inﬂammation. In our experiments, MC degranulation signiﬁ-
cantly reduced the early phase of pain evoked by BK
iontophoresis, but did not prevent the sensitising effects of BK.
There is a mixed literature on the effects of BK on MCs. BK is well
recognised to evoke a ﬂare and wheal response in human skin
[34,59] and indeed, was seen in the present study. The ﬂare re-
sponse has been reported to be abolished by both cyclooxygenase
[14] and histamine receptor inhibitors [23] and by compound 4880
treatment [59]. However, BK is also reported not to directly stimu-
late release of histamine from human skin MCs in vitro [6,12,39],
and has been found to increase permeability in vivo via a largely
histamine-independent mechanism [26,33]. One explanation for
these different ﬁndings is that MCs behave differently in vivoand in vitro. Alternatively, BK may activate MCs indirectly
in vivo, via yet another cell type.
We did not see any effect of MC degranulation on the sensitising
action of BK, further reinforcing the notion that separate mecha-
nisms may be responsible for the sensitising and pain-producing
effects. MC products can contribute to nociceptor sensitisation un-
der certain circumstances [21], but there is no direct evidence that
this is the case when BK is the sensitising agent. The most parsimo-
nious explanation is that BK acts to directly sensitise nociceptors at
low doses, and at higher doses, releases mediators from other cell
types, including MCs that activate nociceptors and cause pain.
Other studies have dissociated pain-producing and ﬂare responses
to BK [33,34], as we too found here.
The role of B1 receptors is controversial. Under normal condi-
tions, most reports claim that nociceptors express B2 but not B1
receptors (but see [62]). B1 receptors are, however, upregulated
in nociceptors under inﬂammatory conditions [27]. Des-Arg9-BK
is a known B1 receptor selective agonist [8,44] with 10,000 lower
afﬁnity than that of BK for the constitutively expressed B2 recep-
tors. Our studies using these 2 agonists support the conventional
rule. That is, that in normal skin, the B1 agonists produced much
less pain and thermal sensitisation than seen with the B2 agonist.
In contrast, we found that thermal and mechanical hyperalgesia
were induced to a similar degree by both agonists in UVB-inﬂamed
skin. These latter observations also suggest that effects of des-
Arg9-BK in normal skin were unlikely to be due to other factors
such as inadequacy of delivery.
Our data also inform on the role of B1 and B2 receptors in vas-
cular responses to BK. We found that des-Arg9-BK produced a var-
iable ﬂare response in normal skin and a more consistent effect in
inﬂamed skin. One other study has compared these agonists in hu-
man skin using a microdialysis technique, and also compared nor-
mal and UVB-inﬂamed skin [22]. That study also concluded that
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In conclusion, this study reports a reliable and noninvasive
method for assessing the algogenic effects of BK in humans. We
have been able to dissociate several distinct effects of BK, including
the effects of B1 vs B2R agonists. This may be particularly useful for
analgesic drug development programmes because there is an
ongoing interest in developing B1 antagonists as analgesic drugs.
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